glp 1 aging America is embarking on a risky experiment with GLP-1s and Glucagon-like peptide-1 receptor: mechanisms and

However, this requires exceptional care, ongoing monitoring, and honest assessment of whether the medication is truly supporting recovery or allowing avoidance of the difficult emotional work that recovery requires

Future large-scale randomized trials with extended follow-up and standardized respiratory endpoints are warranted to clarify durability and causal mechanisms

(2016b)

Molecular physiology of glucagon-like peptide-1 insulin secretagogue action in pancreatic beta cells

The role of adjuvant pharmacotherapy in the management of patients with a partial response to bariatric metabolic surgery-the first Australian experience